Abstract
Sodium-Glucose co-transporter inhibitors are a novel class of drugs widely used in the treatment of type 2 diabetes mellitus medical management. This class of drugs has a simple mechanism of action by which they decrease blood glucose levels. They prevent the uptake or re-absorption of glucose in the blood by inhibiting the SGLT2 co-transport channels located in the renal proximal convoluted tubule. Since SGLT2 is the low affinity, high capacity glucose transporter, it allows the co-transport of sodium and glucose through it. SGLT2s are accountable for around 90% of the renal glucose reuptake. Cerebrovascular complications or accidents (CVAs) are the world's leading cause of mortality, resulting in around 6 million deaths annually. Diabetics are prone to develop mitochondrial dysfunction and neurodegeneration due to hyperglycemia and oxidative stress end products. Due to hyperglycemic condition in diabetes, it is always an elevated risk of cerebrovascular dysfunction due to hyperglycemia as it includes endothelial dysfunction, atherosclerosis, hypercoagulability, oxidative stress, renal reperfusion injury which may lead to neuronal degeneration and cognitive impairment. A diabetic individual is more prone to develop risk factors for transient ischemic attacks than a non-diabetic patient. These inhibitors reduce hyperglycemia by blocking renal glucose reabsorption, therefore promoting an increase in renal glucose excretion. This review discusses the potential role of SGLT2 inhibitors in treating CVAs associated with T2DM.
Keywords: SGLT2 inhibitors, cerebrovascular accident, diabetes, hyperglycemia, vascular damage, stroke.
Current Drug Targets
Title:Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics
Volume: 22 Issue: 14
Author(s): Vishal Chavda, Ruju Vashi and Snehal Patel*
Affiliation:
- Department of Pharmacology, Institute of Pharmacy, Nirma University, Ahmadabad, Gujarat,India
Keywords: SGLT2 inhibitors, cerebrovascular accident, diabetes, hyperglycemia, vascular damage, stroke.
Abstract: Sodium-Glucose co-transporter inhibitors are a novel class of drugs widely used in the treatment of type 2 diabetes mellitus medical management. This class of drugs has a simple mechanism of action by which they decrease blood glucose levels. They prevent the uptake or re-absorption of glucose in the blood by inhibiting the SGLT2 co-transport channels located in the renal proximal convoluted tubule. Since SGLT2 is the low affinity, high capacity glucose transporter, it allows the co-transport of sodium and glucose through it. SGLT2s are accountable for around 90% of the renal glucose reuptake. Cerebrovascular complications or accidents (CVAs) are the world's leading cause of mortality, resulting in around 6 million deaths annually. Diabetics are prone to develop mitochondrial dysfunction and neurodegeneration due to hyperglycemia and oxidative stress end products. Due to hyperglycemic condition in diabetes, it is always an elevated risk of cerebrovascular dysfunction due to hyperglycemia as it includes endothelial dysfunction, atherosclerosis, hypercoagulability, oxidative stress, renal reperfusion injury which may lead to neuronal degeneration and cognitive impairment. A diabetic individual is more prone to develop risk factors for transient ischemic attacks than a non-diabetic patient. These inhibitors reduce hyperglycemia by blocking renal glucose reabsorption, therefore promoting an increase in renal glucose excretion. This review discusses the potential role of SGLT2 inhibitors in treating CVAs associated with T2DM.
Export Options
About this article
Cite this article as:
Chavda Vishal , Vashi Ruju and Patel Snehal *, Cerebrovascular Complications of Diabetes: SGLT-2 Inhibitors as a Promising Future Therapeutics, Current Drug Targets 2021; 22 (14) . https://dx.doi.org/10.2174/1389450121666201020163454
DOI https://dx.doi.org/10.2174/1389450121666201020163454 |
Print ISSN 1389-4501 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-5592 |
Call for Papers in Thematic Issues
Drug-Targeted Approach with Polymer Nanocomposites for Improved Therapeutics
Polymer nanocomposites have been recognized as an advanced and cutting-edge technique in drug targeting administration. These materials combine the unique features of nanoparticles with the adaptability of polymers to produce highly personalized drug administration devices. Integrating nanoparticles containing pharmaceuticals into a polymer matrix enables researchers to regulate the rates at ...read more
RNA Molecules in the Treatment of Human Diseases
Messenger and non-coding RNAs, including long and small transcripts, are mediators of gene expression. Gene expression at the RNA level shows significant aberrations in human diseases, including cancer, leukemia, lymphoma, cardiovascular diseases, and neurological disorders. Human transcripts serve either as biomarkers of diagnosis, prognosis, prediction of treatment response and/or therapy ...read more
![](/images/wayfinder.jpg)
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
Related Articles
-
Exploring the use of Estrogen & Progesterone Replacement Therapy in Subarachnoid Hemorrhage
Current Drug Safety Tuberculous Lymphadenitis in Southern Italy: Clinical Aspects and Treatment Perspectives
Anti-Infective Agents Cerebroprotective Functions of HO-2
Current Pharmaceutical Design Purinergic Signalling and Endothelium
Current Vascular Pharmacology Lifestyle Factors and Endothelial Function
Current Vascular Pharmacology Nitric Oxide and Dietary Factors: Part III Minerals, Vitamins and Other Dietary and Lifestyle Factors
Vascular Disease Prevention (Discontinued) Arterial Hyperoxia in Severe Head Injury: A Useful or Harmful Option?
Current Pharmaceutical Design Comparative Study of Eudragit RS 100 and RL 100 Nanoparticles as Ophthalmic Vehicle for Fungal Infection
Pharmaceutical Nanotechnology Involvement of Orexigenic Peptides in the Mechanism of Gastric Mucosal Integrity and Healing of Chronic Gastric Ulcers
Current Pharmaceutical Design Recent Patents on Ocular Drug Delivery Systems
Recent Patents on Drug Delivery & Formulation Synthesis and Biological Evaluation of Novel Pyrazole Derivatives as Anti-Inflammatory Antimicrobial Agents
Medicinal Chemistry Collateral Circulation in Chronic Total Occlusions – an interventional perspective
Current Cardiology Reviews Pharmacological Management of No Reflow During Percutaneous Coronary Intervention
Current Vascular Pharmacology Olmesartan Associated Enteropathy: Usefulness of Video Capsule Endoscopy in a Case With Doubtful Upper Endoscopic/Histological Picture
Current Drug Safety Exercise Rehabilitation for the Patient with Intermittent Claudication: A highly Effective yet Underutilized Treatment
Current Drug Targets - Cardiovascular & Hematological Disorders Role of Ischemic Blood-Brain Barrier on Amyloid Plaques Development in Alzheimers Disease Brain
Current Neurovascular Research Gum-Chewing and Headache: An Underestimated Trigger of Headache Pain in Migraineurs?
CNS & Neurological Disorders - Drug Targets Nitric Oxide and Dietary Factors: Part II Cholesterol, Fat, Amino Acids,Proteins and Carbohydrate
Vascular Disease Prevention (Discontinued) SGLT2 Inhibitors and Diabetic Kidney Disease: Targeting Multiple and Interrelated Signaling Pathways for Renal Protection
Current Molecular Pharmacology Recurrent Gastrointestinal Bleeding in a Patient with Eisenmenger Syndrome Using Bosentan
Current Drug Safety